Press Release
View printer-friendly version
Materialise Reports Fourth Quarter 2017 Results
LEUVEN,
Highlights – Fourth Quarter 2017
- Total revenue increased 42.1% from the fourth quarter of 2016 to 44,733 kEUR.
- Adjusted EBITDA increased 42.2% from 4,455 kEUR for the fourth quarter of 2016 to 6,334 kEUR.
-
Net profit was 1,528 kEUR, or
0.03 EUR per diluted share, compared to 628 kEUR, or0.01 EUR per diluted share, over the same period last year.
Introduction
Executive Chairman
ACTech Acquisition
On
Fourth Quarter 2017 Results
Total revenue for the fourth quarter of 2017 increased 42.1% to 44,733 kEUR compared to 31,477 kEUR for the fourth quarter of 2016. Excluding the impact of the ACTech acquisition, revenue increased 10.5% to 34,768 kEUR. Total deferred revenue from annual software sales and maintenance contracts amounted to 18,723 kEUR at the end of the fourth quarter of 2017 compared 16,799 kEUR at the end of the fourth quarter of 2016. Adjusted EBITDA, which in the fourth quarter of 2017 excluded 343 kEUR of expenses related to the ACTech acquisition, increased to 6,334 kEUR from 4,455 kEUR, primarily as a result of the revenue contributed by ACTech. Excluding the impact of the ACTech acquisition, Adjusted EBITDA decreased slightly to 4,263 kEUR. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) in the fourth quarter of 2017 was 14.2% (12.3% excluding the impact of the ACTech acquisition) compared to 14.2% in the fourth quarter of 2016.
Revenue from our Materialise Software segment increased 29.6% to 10,468 kEUR for the fourth quarter of 2017 from 8,078 kEUR for the same quarter last year, boosted by original equipment manufacturer (“OEM”) sales growth of 46.7%. Segment EBITDA increased to 4,619 kEUR from 2,949 kEUR while the segment EBITDA margin was 44.1% compared to 36.5% in the prior-year period.
Revenue from our Materialise Medical segment increased 17.7% to 11,842 kEUR for the fourth quarter of 2017 compared to 10,061 kEUR for the same period in 2016. Compared to the same quarter in 2016, revenues from our medical software grew 9.9%, and revenues from medical devices and services grew 22.9%. Segment EBITDA was 2,158 kEUR compared to 656 kEUR while the segment EBITDA margin increased to 18.2% from 6.5 % in the fourth quarter of 2016.
Revenue from our Materialise Manufacturing segment increased 68.0% to 22,394 kEUR for the fourth quarter of 2017 from 13,326 kEUR for the fourth quarter of 2016. Segment EBITDA increased to 1,905 kEUR from 1,438 kEUR while the segment EBITDA margin decreased to 8.5% from 10.8% for the same quarter in 2016. In particular, ACTech contributed revenue of 9,965 kEUR and segment EBITDA of 2,071 kEUR (and segment EBITDA margin of 20.8%). Excluding the impact of the ACTech acquisition, revenue decreased 6.7% to 12,429 kEUR, and segment EBITDA decreased to (166) kEUR.
Gross profit was 24,048 kEUR, or 53.8% of total revenue, for the fourth quarter of 2017. Excluding the impact of the ACTech acquisition, gross profit was 21,421 kEUR, or 61.6% of total revenue, compared to 18,619 kEUR, or 59.2% of total revenue, for the fourth quarter of 2016.
Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 32.8% to 24,553 kEUR for the fourth quarter of 2017 from 18,483 kEUR for the fourth quarter of 2016. Excluding the impact of the ACTech acquisition, operating expenses increased, in the aggregate, 19.1% to 22,017 kEUR. R&D expenses increased from 4,161 kEUR to 5,535 kEUR while S&M expenses increased from 9,506 kEUR to 9,711 kEUR, and G&A expenses increased from 4,816 kEUR to 6,771 kEUR, primarily representing non-recurring expenses, including 343 kEUR related to the acquisition of ACTech.
Net other operating income increased by 192 kEUR to 1,971 kEUR compared to 1,779 kEUR for the fourth quarter of 2016. Excluding the impact of the ACTech acquisition, net other operating income decreased by 193 kEUR. Net other operating income consists primarily of withholding tax exemptions for qualifying researchers, development grants, partial funding of R&D projects and currency exchange results on purchase and sales transactions.
Operating result decreased to 1,466 kEUR from 1,915 kEUR for the same period in the prior year. Excluding the impact of the ACTech acquisition, operating result amounted to 990 kEUR. This decrease was the result of the 19.1% increase in operating expenses, which was offset in part by the 15.0% increase in gross profit. The operating result was also negatively affected by depreciation expenses, which increased to 4,488 kEUR (2,894 kEUR excluding the impact of the ACTech acquisition) from 2,280 kEUR for the fourth quarter of 2016, and by 343 kEUR of expenses related to the acquisition of ACTech.
Net financial result was (356) kEUR compared to 253 kEUR for the prior-year period. The financial result included (269) kEUR net financial expenses related to ACTech. Excluding the impact of the ACTech acquisition, the variances primarily reflected increases in interest expense on the company's financial debt and variances in the currency exchange rates, primarily on the portion of the company’s IPO proceeds held in U.S. dollars versus the euro.
Net profit for the fourth quarter of 2017 was 1,528 kEUR (1,253 kEUR excluding the impact of the ACTech acquisition) compared to net profit of 620 kEUR for the same period in 2016. The decrease in operating profit of 449 kEUR was offset by an increase of 777 kEUR in the company’s share in the result of a joint venture, and an increase of 1,189 kEUR in income tax. Total comprehensive income for the fourth quarter of 2017, which includes exchange differences on translation of foreign operations, was 1,319 kEUR compared to 685 kEUR for the same period in 2016.
At
Net shareholders’ equity at
Full Year 2017 Results
Total revenues for the year ended
Revenues from our Materialise Software segment increased 18.8% to
35,770 kEUR for the year ended
Revenues from our Materialise Medical segment grew by 13.0% for the year
ended
Revenues from our Materialise Manufacturing segment increased 37.3% to
63,712 kEUR (15.8% to 53,747 kEUR excluding the impact of the ACTech
acquisition) for the year ended
Net loss improved from (3,019) kEUR for 2016 to a net loss of (1,656) kEUR for 2017.
2018 Guidance
Mr. Leys concluded, “The additive manufacturing market continues to evolve, particularly in the direction of end part production, and we intend to continue positioning Materialise to benefit from this promising growth market in the coming years. In 2018, we intend to give particular attention to the significant partnerships that we have entered into and to the strategic initiatives that we have launched over the previous years. Simultaneously, in 2018 we will continue to sustain our leadership position in software through continued innovation and strategic partnerships; to drive the next stage of growth in our medical segment, including by entering into partnerships and rolling out our software and planning backbone; and to continue increasing our manufacturing of complex and unique parts. We anticipate delivering sales and Adjusted EBITDA margin expansion in 2018 while reinvesting efficiency gains in selected business development initiatives.
“For fiscal 2018, we expect to report consolidated revenue between 180,000 kEUR - 185,000 kEUR and Adjusted EBITDA between 22,000 kEUR - 25,000 kEUR. We expect our financial results to be particularly strong in the third quarter and even stronger in the fourth quarter. We expect the amount of deferred revenue that Materialise generates from annual licenses and maintenance in 2018 to increase by an amount between 2,000 kEUR – 4,000 kEUR.”
Non-IFRS Measures
Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding non-cash stock-based compensation expenses and acquisition-related expenses of business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company's day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company's business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company's ability to grow or as a valuation measurement. The company's calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company's presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This press release contains translations of certain euro amounts into
U.S. dollars at specified rates solely for the convenience of readers.
Unless otherwise noted, all translations from euros to U.S. dollars in
this press release were made at a rate of
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast to
discuss its financial results for the fourth quarter of 2017 on the same
day,
To access the conference call, please dial 844-469-2530 (U.S.) or 765-507-2679 (international), passcode #7084959. The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com.
A webcast of the conference call will be archived on the company's website for one year.
About Materialise
Materialise incorporates more than 25 years of 3D printing experience
into a range of software solutions and 3D printing services, which
Materialise seeks to form the backbone of the 3D printing industry.
Materialise’s open and flexible solutions enable players in a wide
variety of industries, including healthcare, automotive, aerospace, art
and design, and consumer goods, to build innovative 3D printing
applications that aim to make the world a better and healthier place.
Headquartered in
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended,
regarding, among other things, our intentions, beliefs, assumptions,
projections, outlook, analyses or current expectations, plans,
objectives, strategies and prospects, both financial and business,
including statements concerning, among other things, current estimates
of fiscal 2018 revenues, deferred revenue from annual licenses and
maintenance and Adjusted EBITDA, the benefits of the ACTech acquisition,
results of operations, cash needs, capital expenditures, expenses,
financial condition, liquidity, prospects, growth and strategies
(including our strategic priorities for 2018), and the trends and
competition that may affect the markets, industry or us. Such statements
are subject to known and unknown uncertainties and risks. When used in
this press release, the words “estimate,” “expect,” “anticipate,”
“project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,”
“could,” “might,” “aim,” “should,” and variations of such words or
similar expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon the expectations of
management under current assumptions at the time of this press release.
These expectations, beliefs and projections are expressed in good faith
and the company believes there is a reasonable basis for them. However,
the company cannot offer any assurance that our expectations, beliefs
and projections will actually be achieved. By their nature,
forward-looking statements involve risks and uncertainties because they
relate to events, competitive dynamics and industry change, and depend
on economic circumstances that may or may not occur in the future or may
occur on longer or shorter timelines than anticipated. We caution you
that forward-looking statements are not guarantees of future performance
and involve known and unknown risks, uncertainties and other factors
that are in some cases beyond our control. All of the forward-looking
statements are subject to risks and uncertainties that may cause the
company's actual results to differ materially from our expectations,
including risk factors described in the company's annual report on Form
20-F filed with the
The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
Consolidated income statements (Unaudited) |
|||||||||||
For the three months |
For the twelve |
||||||||||
(in thousands, except per share amounts) | 2017 | 2017 | 2016 | 2017 | 2016 | ||||||
U.S.$ | € | € | € | € | |||||||
Revenue | 53,648 | 44,733 | 31,477 | 142,573 | 114,477 | ||||||
Cost of sales | (24,808) | (20,685) | (12,858) | (62,787) | (46,706) | ||||||
Gross profit | 28,840 | 24,048 | 18,619 | 79,786 | 67,771 | ||||||
Gross profit as % of revenue | 53.8% | 53.8% | 59.2% | 56.0% | 59.2% | ||||||
Research and development expenses | (6,638) | (5,535) | (4,161) | (19,959) | (17,682) | ||||||
Sales and marketing expenses | (12,879) | (10,739) | (9,506) | (39,109) | (36,153) | ||||||
General and administrative expenses | (9,929) | (8,279) | (4,816) | (25,484) | (20,041) | ||||||
Net other operating income (expenses) | 2,364 | 1,971 | 1,779 | 5,631 | 6,212 | ||||||
Operating (loss) profit | 1,758 | 1,466 | 1,915 | 865 | 107 | ||||||
Financial expenses | (1,720) | (1,434) | (749) | (4,728) | (2,437) | ||||||
Financial income | 1,293 | 1,078 | 1,002 | 3,210 | 2,039 | ||||||
Share in loss of joint venture | 152 | 127 | (650) | (469) | (1,018) | ||||||
(Loss) profit before taxes | 1,483 | 1,237 | 1,518 | (1,122) | (1,309) | ||||||
Income taxes | 349 | 291 | (898) | (534) | (1,710) | ||||||
Net (loss) profit of the period | 1,832 | 1,528 | 620 | (1,656) | (3,019) | ||||||
Net (loss) profit attributable to: | |||||||||||
The owners of the parent | 1,832 | 1,528 | 620 | (1,656) | (3,019) | ||||||
Non-controlling interest | − | − | − | − | − | ||||||
Earnings per share attributable to the owners of the parent | |||||||||||
Basic | 0.04 | 0.03 | 0.01 | (0.03) | (0.06) | ||||||
Diluted | 0.04 | 0.03 | 0.01 | (0.03) | (0.06) | ||||||
Weighted average basic shares outstanding | 47,325 | 47,325 | 47,325 | 47,325 | 47,325 | ||||||
Weighted average diluted shares outstanding | 48,467 | 48,467 | 47,325 | 47,325 | 47,325 | ||||||
Consolidated statements of comprehensive income (Unaudited) |
|||||||||||
For the three months |
For the twelve |
||||||||||
(in thousands) | 2017 | 2017 | 2016 | 2017 | 2016 | ||||||
U.S.$ | € | € | € | € | |||||||
Net profit (loss) for the period | 1,832 | 1,528 | 620 | (1,656) | (3,019) | ||||||
Other comprehensive income | |||||||||||
Exchange difference on translation of foreign operations | (252) | (210) | 65 | (691) | (1,833) | ||||||
Other comprehensive income (loss), net of taxes | (252) | (210) | 65 | (691) | (1,833) | ||||||
Total comprehensive income (loss) for the year, net of taxes | 1,580 | 1,319 | 685 | (2,347) | (4,852) | ||||||
Total comprehensive income (loss) attributable to: | |||||||||||
The owners of the parent | 1,580 | 1,319 | 685 | (2,347) | (4,852) | ||||||
Non-controlling interest | − | − | − | − | − | ||||||
Consolidated statements of financial position (Unaudited) |
|||||
As of December 31 | |||||
(in thousands) | 2017 | 2016 | |||
€ | € | ||||
Assets | |||||
Non-current assets |
|||||
Goodwill |
18,447 |
8,860 | |||
Intangible assets |
28,646 |
9,765 | |||
Property, plant & equipment | 86,881 | 45,063 | |||
Investments in joint ventures | 31 | − | |||
Deferred tax assets | 304 | 336 | |||
Other non-current assets | 3,667 | 2,154 | |||
Total non-current assets |
137,976 |
66,178 | |||
Current assets |
|||||
Inventories and contracts in progress | 11,594 | 7,870 | |||
Trade receivables | 35,582 | 27,479 | |||
Other current assets | 9,212 | 4,481 | |||
Cash and cash equivalents | 43,175 | 55,912 | |||
Total current assets | 99,563 | 95,742 | |||
Total assets |
237,539 |
161,920 | |||
As of December 31 | |||||
(in thousands) | 2017 | 2016 | |||
€ | € | ||||
Equity and liabilities | |||||
Equity | |||||
Share capital | 2,729 | 2,729 | |||
Share premium | 79,839 | 79,019 | |||
Consolidated reserves | (3,250) | (1,603) | |||
Other comprehensive income | (1,803) | (1,112) | |||
Equity attributable to the owners of the parent | 77,515 | 79,033 | |||
Non-controlling interest | − | − | |||
Total equity | 77,515 | 79,033 | |||
Non-current liabilities |
|||||
Loans & borrowings | 81,788 | 28,267 | |||
Deferred tax liabilities |
7,006 |
1,325 | |||
Deferred income | 5,040 | 3,588 | |||
Other non-current liabilities | 1,904 | 1,873 | |||
Total non-current liabilities |
95,738 |
35,053 | |||
Current liabilities |
|||||
Loans & borrowings | 12,769 | 5,539 | |||
Trade payables | 15,670 | 13,400 | |||
Tax payables | 3,560 | 926 | |||
Deferred income | 18,791 | 17,822 | |||
Other current liabilities | 13,496 | 10,147 | |||
Total current liabilities |
64,286 | 47,834 | |||
Total equity and liabilities |
237,539 |
161,920 | |||
Consolidated statements of cash flows (Unaudited) |
|||||
For the twelve |
|||||
(in thousands) | 2017 | 2016 | |||
€ | € | ||||
Operating activities | |||||
Net (loss) profit of the period | (1,656) | (3,019) | |||
Non-cash and operational adjustments | |||||
Depreciation of property, plant & equipment | 8,630 | 6,420 | |||
Amortization of intangible assets | 4,001 | 1,954 | |||
Share-based payment expense | 1,033 | 977 | |||
Loss (gain) on disposal of property, plant & equipment | 25 | (149) | |||
Fair value contingent liabilities | − | (455) | |||
Movement in provisions | 61 | 18 | |||
Movement reserve for bad debt | 502 | 77 | |||
Financial income | (381) | (172) | |||
Financial expense | 1,597 | 983 | |||
Impact of foreign currencies | 302 | (400) | |||
Share in loss of a joint venture (equity method) | 469 | 1,018 | |||
(Deferred) Income taxes | 534 | 1,712 | |||
Other | (22) | (78) | |||
Working capital adjustment & income tax paid | |||||
Increase in trade receivables and other receivables |
(6,510) |
(6,465) | |||
Decrease (increase) in inventories | (984) | (2,482) | |||
Increase in trade payables and other payables | 3,854 | 9,086 | |||
Income tax paid | (1,569) | (530) | |||
Net cash flow from operating activities |
9,886 |
8,495 | |||
For the twelve |
|||||
(in thousands) | 2017 | 2016 | |||
€ | € | ||||
Investing activities | |||||
Purchase of property, plant & equipment | (27,668) | (12,237) | |||
Purchase of intangible assets | (4,345) | (2,342) | |||
Proceeds from the sale of property, plant & equipment & intangible assets (net) | 221 | 1,928 | |||
Acquisition of subsidiary |
(27,173) |
− | |||
Investments in joint-ventures | (500) | − | |||
Interest received | 281 | 11 | |||
Net cash flow used in investing activities |
(59,184) |
(12,640) | |||
Financing activities | |||||
Proceeds from loans & borrowings | 54,319 | 14,669 | |||
Repayment of loans & borrowings | (11,904) | (2,796) | |||
Repayment of finance leases | (2,947) | (1,898) | |||
Interest paid | (955) | (630) | |||
Other financial income (expense) | (472) | (79) | |||
Net cash flow from (used in) financing activities | 38,041 | 9,266 | |||
Net increase of cash & cash equivalents | (11,257) | 5,121 | |||
Cash & cash equivalents at beginning of the year | 55,912 | 50,726 | |||
Exchange rate differences on cash & cash equivalents | (1,480) | 65 | |||
Cash & cash equivalents at end of the year | 43,175 | 55,912 | |||
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) |
|||||||||
For the three months |
For the twelve |
||||||||
(in thousands) | 2017 | 2016 | 2017 | 2016 | |||||
€ | € | € | € | ||||||
Net profit (loss) for the period | 1,528 | 620 | (1,656) | (3,019) | |||||
Income taxes | (291) | 898 | 534 | 1,710 | |||||
Financial expenses | 1,434 | 749 | 4,728 | 2,437 | |||||
Financial income | (1,078) | (1,002) | (3,210) | (2,039) | |||||
Share in loss of joint venture | (127) | 650 | 469 | 1,018 | |||||
Depreciation and amortization | 4,489 | 2,280 | 12,631 | 8,374 | |||||
EBITDA | 5,955 | 4,195 | 13,496 | 8,481 | |||||
Non-cash stock-based compensation expense (1) | 36 | 260 | 1,033 | 977 | |||||
Acquisition-related expenses of business combinations | 343 | − | 609 | − | |||||
ADJUSTED EBITDA | 6,334 | 4,455 | 15,138 | 9,458 | |||||
(1) | Non-cash stock-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees. | |
Segment P&L (Unaudited) |
|||||||||||||
(in thousands) |
Materialise |
Materialise |
Materialise |
Total |
Unallocated |
Consoli- |
|||||||
€ | € | € | € | € | € | ||||||||
For the three months ended December 31, 2017 | |||||||||||||
Revenues | 10,468 | 11,842 | 22,394 | 44,704 | 29 | 44,733 | |||||||
Segment EBITDA | 4,619 | 2,158 | 1,905 | 8,682 | (2,727) | 5,955 | |||||||
Segment EBITDA % |
44.1% | 18.2% | 8.5% | 19.4% | 13.3% | ||||||||
For the three months ended December 31, 2016 | |||||||||||||
Revenues | 8,078 | 10,061 | 13,326 | 31,465 | 12 | 31,477 | |||||||
Segment EBITDA | 2,949 | 656 | 1,438 | 5,043 | (848) | 4,195 | |||||||
Segment EBITDA % |
36.5% | 6.5% | 10.8% | 16.0% | 13.3% | ||||||||
(in thousands) |
Materialise |
Materialise |
Materialise |
Total |
Unallocated |
Consoli- |
|||||||
€ | € | € | € | € | € | ||||||||
For the twelve months ended December 31, 2017 | |||||||||||||
Revenues | 35,770 | 42,841 | 63,712 | 142,323 | 250 | 142,573 | |||||||
Segment EBITDA | 13,926 | 4,400 | 4,967 | 23,293 | (9,797) | 13,496 | |||||||
Segment EBITDA % |
38.9% | 10.3% | 7.8% | 16.4% | 9.5% | ||||||||
For the twelve months ended December 31, 2016 | |||||||||||||
Revenues | 30,122 | 37,910 | 46,406 | 114,438 | 39 | 114,477 | |||||||
Segment EBITDA | 10,130 | 894 | 3,848 | 14,872 | (6,391) | 8,481 | |||||||
Segment EBITDA % |
33.6% | 2.4% | 8.3% | 13.0% | 7.4% | ||||||||
Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited) |
|||||||||
For the three months |
For the twelve |
||||||||
(in thousands) | 2017 | 2016 | 2017 | 2016 | |||||
€ | € | € | € | ||||||
Net profit (loss) for the period | 1,528 | 620 | (1,656) | (3,019) | |||||
Income taxes | (291) | 898 | 534 | 1,710 | |||||
Finance cost | 1,434 | 749 | 4,728 | 2,437 | |||||
Finance income | (1,078) | (1,002) | (3,210) | (2,039) | |||||
Share in loss of joint venture | (127) | 650 | 469 | 1,018 | |||||
Operating profit | 1,466 | 1,915 | 865 | 107 | |||||
Depreciation and amortization | 4,489 | 2,280 | 12,631 | 8,374 | |||||
Corporate research and development | 490 | 472 | 2,017 | 1,673 | |||||
Corporate headquarter costs | 2,706 | 1,781 | 9,690 | 8,646 | |||||
Other operating income (expense) | (469) | (1,405) | (1,910) | (3,928) | |||||
Segment EBITDA | 8,682 | 5,043 | 23,293 | 14,872 |
View source version on businesswire.com: http://www.businesswire.com/news/home/20180306005277/en/
Source:
Investors:
LHA
Harriet Fried/Jody Burfening
212-838-3777
hfried@lhai.com